COPD: Inhaled Triple Therapy and Device Choice

B.C. Provincial Academic Detailing (PAD) Service **October 2024**

Slide 2 Overview

1. McKesson Canada. PharmaClik. https://pharmaclik-login.mckesson.ca/
2. IMPACT 2018: main publication, clinicaltrials.gov, clinical study report, FDA review, secondary publications
   a) N Engl J Med 2018;378:1671-80
   b) NCT02164513
   c) Dransfield M et al. Ann Am Thorac Soc 2021;18:788-98
   d) Lipson D et al. Am J Respir Crit Care Med 2020;201:1508-16
   e) Han M et al. Am J Respir Crit Care Med 2020;9:1237-43
   f) Pascoe S et al. Lancet Respir Med 2019;7:745-756
   g) Tabberer M et al. Adv Ther 2020;37:3775-90
3. IMPACT Clinical Study Report https://www.gsk-studyregister.com/en/trial-details/?id=4871&oldId=true
4. US FDA Review 2020 Trelegy Ellipta. FDA Briefing Document. Pulmonary-Allergy Drugs Advisory Committee Meeting. August 31, 2020. Archived.
5. ETHOS 2020: main publication, clinicaltrials.gov, FDA review, secondary publications
   a) N Engl J Med 2020;383:35-48
   b) NCT02465567
   c) Martinez F et al. Respir Med 2021;185:106509
   d) Martinez F et al. Am J Respir Crit Care Med 2021;203:553-64
   e) Singh D et al. Respir Med 2022;197:106857
   f) Rabe K et al. Eur Resp J 2020;56:984
6. US FDA 2020 Drug Approval Package: Breztri Aerosphere https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212122Orig1s000TOC.cfm
7. US FDA 2023 Warning Letter: AstraZeneca Pharmaceuticals LP. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/astrazeneca-pharmaceuticals-lp-664789-08042023
8. Health Canada Drug Product Database https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html
   - Trelegy Ellipta Product Monograph
   - Breztri Aerosphere Product Monograph
9. US FDA Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   - Trelegy Ellipta Labeling Package Insert
   - Breztri Aerosphere Labeling Package Insert
10. IMPACT 2018. Halpin D et al. Eur Resp J 2020;55:1901921
11. IMPACT 2018. Pascoe S et al. Lancet Respir Med 2019;7:745-756
12. ETHOS 2020. Bafadhel M et al. Int J Chron Obstruct Pulmon Dis 2022;17:3061-73
13. ERS. European Respiratory Society. Withdrawal of inhaled corticosteroids in COPD. Eur Resp J 2020;55:2000351
14. CTS. Canadian Thoracic Society 2023. Guidance on Pharmacotherapy in Patients with Stable COPD. Chest 2023;164:1159-83
15. GOLD. Global Initiative for Chronic Obstructive Lung Disease 2024 Report. https://goldcopd.org/2024-gold-report/
16. Cochrane Database Systematic Reviews 2014. CD009285. Tiotropium.
17. Cochrane Database Systematic Reviews 2014. CD010509. Aclidinium.
18. Cochrane Database Systematic Reviews 2017. CD0111897. Umeclidinium.
19. SPARK. Lancet Respir Med 2013;1:199-209
20. DYNAGITO. Lancet Respir Med 2018;6:337-344

Slide 3 Guidelines, Evidence

1. Canadian Thoracic Society. 2023 Guidance on Pharmacotherapy in Patients with Stable COPD. Chest 2023;164:1159-83
2. EMAX 2019: main publication, clinicaltrials.gov, clinical study report, secondary publications
   a) Respir Res 2019;20:238
   b) NCT03034915
   c) Kerwin E et al. Ther Adv Respir Dis 2020;14:1-11
3. EMAX Clinical Study Report https://www.gsk-studyregister.com/en/trial-details/?id=201749
4. SPARK. Lancet Respir Med 2013;1:199-209
5. DYNAGITO. Lancet Respir Med 2018;6:337-344
6. IMPACT 2018: main publication, clinicaltrials.gov, clinical study report, FDA review, secondary publications
   a) N Engl J Med 2018;378:1671-80
   b) NCT02164513
   c) Dransfield M et al. Ann Am Thorac Soc 2021;18:788-98
   d) Lipson D et al. Am J Respir Crit Care Med 2020;201:1508-16
   e) Han M et al. Am J Respir Crit Care Med 2020;9:1237-43

   f) Pascoe S et al. Lancet Respir Med 2019;7:745-756
   g) Halpin D et al. Eur Resp J 2020;55:1901921
   h) Tabberer M et al. Adv Ther 2020;37:3775-90
7. IMPACT Clinical Study Report https://www.gsk-studyregister.com/en/trial-details/?id=4871&oldId=true
8. US FDA Review 2020 Trelegy Ellipta. FDA Briefing Document. Pulmonary-Allergy Drugs Advisory Committee Meeting. August 31, 2020. Archived.
9. ETHOS 2020: main publication, clinicaltrials.gov, FDA review, secondary publications
   a) N Engl J Med 2020;383:35-48
   b) NCT02465567
   c) Martinez F et al. Respir Med 2021;185:106509
   d) Martinez F et al. Am J Respir Crit Care Med 2021;203:553-64
   e) Singh D et al. Respir Med 2022;197:106857
   f) Rabe K et al. Eur Resp J 2020;56:984
   g) Bafadhel M et al. Int J Chron Obstruct Pulmon Dis 2022;17:3061-73
10. US FDA 2020 Drug Approval Package: Breztri Aerosphere https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212122Orig1s000TOC.cfm
11. US FDA 2023 Warning Letter: AstraZeneca Pharmaceuticals LP. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/astrazeneca-pharmaceuticals-lp-664789-08042023
12. GOLD. Global Initiative for Chronic Obstructive Lung Disease 2024 Report. https://goldcopd.org/2024-gold-report/
13. GOLD. Global Initiative for Chronic Obstructive Lung Disease 2016 Report. Archived.

Slide 4 Clinical Considerations

1. Health Canada Drug Product Database https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html
   - Trelegy Ellipta Product Monograph
   - Breztri Aerosphere Product Monograph
2. US FDA Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   - Trelegy Ellipta Labeling Package Insert
   - Breztri Aerosphere Labeling Package Insert
3. Green S et al. Can Fam Phys 2024;70:381-87
4. AstraZeneca Canada Inc. Medical Information. Use of Breztri Aerosphere with a spacer. 15 Feb 2024.
5. GINA. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2023. https://ginasthma.org/2023-gina-main-report/
6. CTS. Canadian Thoracic Society 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults. Can J Resp Crit Care Care Sleep Med 2021;5:348-61
7. CTS. Canadian Thoracic Society 2023 Guidance on Pharmacotherapy in Patients with Stable COPD. Chest 2023;164:1159-83
8. GOLD. Global Initiative for Chronic Obstructive Lung Disease 2024 Report. https://goldcopd.org/2024-gold-report/
9. GOLD. Blood eosinophils and chronic obstructive pulmonary disease 2022 Review. Am J Respir Crit Care Med 2022;206:17-24
10. ERS. European Respiratory Society. Withdrawal of inhaled corticosteroids in COPD. Eur Resp J 2020;55:2000351
11. BC Guidelines. Chronic Obstructive Pulmonary Disease: Diagnosis and Management 2024. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/copd
12. Mathioudakis A et al. Chest 2024; epub 9 July 2024. https://pubmed.ncbi.nlm.nih.gov/38992490/
13. US FDA Approved Drugs https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   - Dupilumab (Dupixent) Package Insert
14. IMPACT N Engl J Med 2018;378:1671-80
15. ETHOS N Engl J Med 2020;383:35-48
16. IMPACT Clinical Study Report https://www.gsk-studyregister.com/en/trial-details/?id=4871&oldId=true
17. Savran O, Urik C. J Ophthalmology 2023;8209978
18. CredibleMeds. Drugs to be avoided by Congenital Long QT Patients. August 8, 2024. https://crediblemeds.org/
19. SUMMIT. Lancet 2016;387:1817-26
20. Gonzales A et al. Chest 2018;153:321-28
21. UpToDate® Lexidrug™

Slide 5 Evidence: outcome details (pdf only)

1. EMAX 2019: main publication, clinicaltrials.gov, clinical study report, secondary publications
   a) Respir Res 2019;20:238
   b) NCT03034915
   c) Kerwin E et al. Ther Adv Respir Dis 2020;14:1-11
2. EMAX Clinical Study Report https://www.gsk-studyregister.com/en/trial-details/?id=201749
3. IMPACT 2018: main publication, clinicaltrials.gov, clinical study report, FDA review, secondary publications
   a) N Engl J Med 2018;378:1671-80
   b) NCT02164513
   c) Dransfield M et al. Ann Am Thorac Soc 2021;18:788-98
   d) Lipson D et al. Am J Respir Crit Care Med 2020;201:1508-16
   e) Han M et al. Am J Respir Crit Care Med 2020;9:1237-43
   f) Pascoe S et al. Lancet Respir Med 2019;7:745-756

   g) Halpin D et al. Eur Resp J 2020;55:1901921
   h) Tabberer M et al. Adv Ther 2020;37:3775-90
4. IMPACT Clinical Study Report https://www.gsk-studyregister.com/en/trial-details/?id=4871&oldId=true
5. US FDA Review 2020 Trelegy Ellipta. FDA Briefing Document. Pulmonary-Allergy Drugs Advisory Committee Meeting. August 31, 2020. Archived.
6. ETHOS 2020: main publication, clinicaltrials.gov, FDA review, secondary publications
   a) N Engl J Med 2020;383:35-48
   b) NCT02465567
   c) Martinez F et al. Respir Med 2021;185:106509
   d) Martinez F et al. Am J Respir Crit Care Med 2021;203:553-64
   e) Singh D et al. Respir Med 2022;197:106857
   f) Rabe K et al. Eur Resp J 2020;56:984
   g) Bafadhel M et al. Int J Chron Obstruct Pulmon Dis 2022;17:3061-73
7. US FDA 2020 Drug Approval Package: Breztri Aerosphere https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212122Orig1s000TOC.cfm
8. US FDA 2023 Warning Letter: AstraZeneca Pharmaceuticals LP. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/astrazeneca-pharmaceuticals-lp-664789-08042023

COPD Device Choice

1. Cataldo D et al. Adv Ther 2022;39:1149-1163
2. Health Canada Drug Product Database. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html
   - Trelegy Ellipta Product Monograph
   - Spiriva Respimat Product Monograph
   - Breztri Aerosphere Product Monograph
3. IMPACT 2018. N Engl J Med 2018;378:1671-80
4. DYNAGITO 2018. Lancet 2018;6:337-44
5. ETHOS 2020. N Engl J Med 2020;383:35-48
6. Boehringer Ingelheim. Medical Information. Use of the Respimat Inhaler with a spacer. 9 Nov 2020
7. AstraZeneca Canada Inc. Medical Information. Use of Breztri Aerosphere with a spacer. 15 Feb 2024
8. Green S et al. Can Fam Phys 2024;70:381-87